2315504-40-4
2315504-40-4
Chemical Structure
DA-JC4
- CAS No.: 2315504-40-4
- Formula:C225H346N56O65
- Molecular Weight:4875.49
InChIKey: VNWKTOKETHGBQD-UHFFFAOYSA-N
SMILES: [Y-{aminoisobutyric acid}-EGTFTSDYSIYLDKQAA-{aminoisobutyric acid}-EFVNWLLAGGPSSGAPPPSKKKKKK-NH2]
Biological Activity: DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DA-JC4 | 99.27% | DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shi L, et al. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;327:65-74. [Content Brief]
- [2]. Feng P, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2018;133:385-394. [Content Brief]
- [3]. Li T, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model. Life Sci. 2020;256:117824. [Content Brief]
